首页> 外国专利> NEXT-GENERATION SEQUENCING ASSAY FOR GENOMIC CHARACTERIZATION AND MINIMAL RESIDUAL DISEASE DETECTION IN THE BONE MARROW, PERIPHERAL BLOOD, AND URINE OF MULTIPLE MYELOMA AND SMOLDERING MYELOMA PATIENTS

NEXT-GENERATION SEQUENCING ASSAY FOR GENOMIC CHARACTERIZATION AND MINIMAL RESIDUAL DISEASE DETECTION IN THE BONE MARROW, PERIPHERAL BLOOD, AND URINE OF MULTIPLE MYELOMA AND SMOLDERING MYELOMA PATIENTS

机译：骨髓，外周血和多发性骨髓瘤和尿瘤尿液尿液中的基因组表征和最小残留疾病检测的下一代测序测定。

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to methods for the personalized detection of Minimal Residual Disease (MRD) from the peripheral blood, urine, or bone marrows through patient-specific translocation breakpoints and VDJ rearrangements, as well as copy number alterations (CNAs) and single nucleotide variants (SNV) specific to Multiple myeloma (MM).

机译：本发明涉及通过患者特异性易位断点和VDJ重排以及VDJ重排和拷贝数改变（CNA）和单核苷酸变体的患者特异性血液，尿液或骨髓的个性化检测的方法。（SNV）特异于多个骨髓瘤（mm）。

著录项

公开/公告号US2021087638A1

专利类型
公开/公告日2021-03-25

原文格式PDF
申请/专利权人 DANA-FARBER CANCER INSTITUTE INC.;
展开▼

申请/专利号US202017029684
发明设计人 IRENE GHOBRIAL;
展开▼

申请日2020-09-23
分类号C12Q1/6886;
国家 US
入库时间 2022-08-24 17:54:41

相似文献

专利
外文文献
中文文献